Roche has recently launched a “fundamental reorganization” of Spark Therapeutics, the gene therapy unit that the Swiss pharma ...

Three months after an FDA approval for cancer immunotherapy Unloxcyt, Checkpoint Therapeutics has found a buyer. | Three ...

With a U.S. green light for its encapsulated cell therapy technology in the bag, privately held biotech Neurotech ...

As Emergent BioSolutions continues to pawn off manufacturing real estate in its pivot from production specialist to full-time ...

Shortly after Starboard Value pitched four nominees for Kenvue's | Activist investor Starboard Value proposed four additions ...

In a statement, Trotter described his experience as a child with older relatives who struggled with Type 2 diabetes. Trotter ...

Presiding over the upward trajectory of Eli Lilly over the last eight years is paying off nicely for CEO David Ricks. | ...

Every year, amid Women’s History Month, March 8 marks International Women’s Day—a day dedicated to both honoring past efforts ...

As Incyte strives to push its topical JAK inhibitor Opzelura into additional dermatology indications, the company’s latest ...

Three months after Bristol Myers Squibb revealed the success of two phase 3 trials of its oral targeted therapy Sotyktu in ...

| Real-world evidence lets us see how HIV medicines work in real life, helping HCPs provide better care and improving ...

By Andrew Gottfried, Chief Executive Officer, Nexus Health Group | As the US healthcare landscape continues to evolve, 2025 is set to bring significant transformations driven by shifting policies, ...